Olaparib is under clinical development by AstraZeneca and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

That is the conclusion of draft guidance which says that the evidence for Lynparza (olaparib) as a treatment for prostate cancer is uncertain, and therefore not a good use of NHS funds.

Australians with prostate and breast cancer now have affordable access to affordable new and expanded medicines under the ...

AstraZeneca and Merck & Co’s Lynparza (olaparib) has massively reduced the risk of BRCA-mutated ovarian cancer progressing in patients who have just been treated with chemo, in trial results ...

December 11, 2024--Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated ...

today announced long-term results from the OlympiA Phase 3 trial which showed LYNPARZA (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive ...

AstraZeneca Pharma India (APIL) was incorporated on July 11 1979. The Company is engaged in the business of manufacture distribution and marketing of pharmaceutical products and co-ordinates clinical ...

In 2023, the global breast cancer drug market is projected to be worth USD 10,733.1 million.  Between 2023 and 2033, the demand for breast cancer drugs is expected to expand at a CAGR of 1.1%, ...